Recurrent Colorectal Carcinoma

Explore clinical trials studying Recurrent Colorectal Carcinoma. Study availability and eligibility vary by location and protocol.

17 public trials 3 recruiting studies

Refine in advanced search Browse all conditions

Recurrent Colorectal Carcinoma trial results

Completed

Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery

NCT02713373

Conditions: Colonic Diseases, Colorectal Neoplasms, Digestive System Diseases, +11 more
Locations: Roswell Park Cancer Institute Buffalo, New York, United States

University Hospitals Seidman Cancer Center Cleveland, Ohio, United States

View Trial Details

Completed

Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver

NCT03403634

Conditions: Colonic Diseases, Colorectal Neoplasms, Digestive System Diseases, +13 more
Locations: Roswell Park Cancer Institute Buffalo, New York, United States

View Trial Details

Completed

Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas

NCT02973672

Conditions: Colon Cancer, Colonic Diseases, Colonic Neoplasms, +19 more
Locations: Catharina Ziekenhuis Eindhoven Eindhoven, Netherlands

Leiden University Medical Center Leiden, Netherlands

Erasmus Medical Center Cancer Institute Rotterdam, Netherlands

View Trial Details

Completed

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

NCT01522820

Conditions: Adenocarcinoma, Adnexal Diseases, Anaplastic Astrocytoma, +137 more
Locations: Roswell Park Cancer Institute Buffalo, New York, United States

View Trial Details

Active, Not Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060

Conditions: Adenocarcinoma, Adnexal Diseases, Advanced Lymphoma, +138 more
Locations: University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States

Thomas Hospital Fairhope, Alabama, United States

Mobile Infirmary Medical Center Mobile, Alabama, United States

University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States

View all 1411 locations

View Trial Details

Active, Not Recruiting

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

NCT04616183

Conditions: Colonic Diseases, Colonic Neoplasms, Colorectal Neoplasms, +41 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

NCT04017650

Conditions: BRAF NP_004324.2:p.V600E, Colonic Diseases, Colonic Neoplasms, +30 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Recurrent Colorectal Carcinoma

Recurrent Colorectal Carcinoma trial results

Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery

Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver

Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

Related conditions